<?xml version="1.0" encoding="UTF-8"?>
<p id="Par12">Several documents from the European Medicines Agency (EMA) speak of the place of ethics in the regulatory processes involved in a marketing authorization application (henceforth, application) [
 <xref ref-type="bibr" rid="CR1">1</xref>–
 <xref ref-type="bibr" rid="CR4">4</xref>]. One of these is the document, 
 <italic>Points to consider on Good Clinical Practice (GCP) inspection findings and the benefit-risk balance</italic> where the mandate of regulators in terms of the place of these ethical issues in the evaluation process is explained as follows:
 <disp-quote>
  <p id="Par13">GCP inspection findings – 
   <italic>even if not directly influencing the benefit-risk balance</italic>—will still be important if they raise serious questions about the rights, safety and well-being of trial subjects and hence the overall ethical conduct of the study. It is an obligation of clinical assessors, rapporteurs and the CHMP also to assess the ethics of a clinical development programme, and major ethical flaws should have an impact on the final conclusions about approvability of an application. Consequently, ethical misconduct could result in rejection of the application [
   <xref ref-type="bibr" rid="CR4">4</xref>]. (
   <italic>italics mine</italic>).
  </p>
 </disp-quote>
</p>
